BRETEC — Bioretec Oy Share News
0.000.00%
Last trade - 00:00- €30.86m
- €27.17m
- €3.52m
Brief: Bioretec Enters Into U.S. Distribution Agreement With Spartan Medical For RemeOs Screws
Brief: Bioretec Receives Research And Development Grant
Brief: Bioretec Aims For Net Sales Of EUR 62 Mln By End-2027
Brief: Bioretec Oy Invests In CNC Machining Center To Increase Remeos Production Capacity
Brief: Bioretec Invests In CNC Machining Center To Increase RemeOsTM Capacity
Brief: Bioretec Says Subscription Price Of Placing Shares Is EUR 2 Per Placing Share
Brief: Bioretec Initiates Private Placement
Brief: Bioretec Updates Its Product Pipeline To Accelerate Commercialization Strategy
Brief: Bioretec Receives FDA Approval For Bioresorbable Metal Product
Brief: Bioretec Says FDA Approves Co's Remeos Trauma Screw As First Bioresorbable Metal Implant In U.S. Market
Brief: Bioretec Board To Reschedule Date Of AGM, Projected Date Is May 26, 2023
Brief: Bioretec H2 Net Loss Narrows To EUR 1.0 Mln
Brief: Bioretec Says Submitted Additional Information Requested By U.S. FDA For Registration Of Remeos Trauma Screws
Brief: Bioretec Has Submitted Additional Information Requested By The FDA For US Registration Of Remeos Trauma Screws
Brief: Bioretec Expects European Marketing Authorization For Remeos Trauma Screw To Be Delayed From Original Estimate Of 2022
Brief: Bioretec Expects FDA Approval For RemeOs Screws In April 2023
Brief: Bioretec's Hybrid Composite Patent Approved In Europe
Brief: Bioretec H1 Net Loss Narrows To EUR 1.4 Mln
Brief: Bioretec Enters Into 5-Year Exclusive Distribution Agreement